Precigen (NASDAQ:PGEN) Director Sells $243,082.80 in Stock

Key Points

• Jeffrey Kindler, a director at Precigen, sold 67,523 shares for approximately $243,082.80, reducing his ownership by 12.97% and retaining around 452,907 shares.
• PGEN shares rose to $3.34, with a market capitalization of $995.22 million, and the company has a 1-year low of $0.65 and a high of $5.22.
• Analysts have a consensus rating of "Moderate Buy" for Precigen, with target prices ranging from $6.00 to $8.50 based on recent reports.

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) Director Jeffrey Kindler sold 67,523 shares of Precigen stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $3.60, for a total transaction of $243,082.80. Following the sale, the director owned 452,907 shares of the company's stock, valued at approximately $1,630,465.20. This represents a 12.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Precigen Price Performance

Shares of PGEN stock traded up $0.05 during trading on Wednesday, reaching $3.34. The company's stock had a trading volume of 4,371,158 shares, compared to its average volume of 4,147,403. The company has a market capitalization of $995.22 million, a price-to-earnings ratio of -7.95 and a beta of 1.82. The stock's 50-day moving average price is $3.18 and its 200 day moving average price is $2.09. Precigen, Inc. has a 1-year low of $0.65 and a 1-year high of $5.22.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. The firm had revenue of $0.86 million during the quarter, compared to analysts' expectations of $0.67 million. On average, sell-side analysts anticipate that Precigen, Inc. will post -0.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PGEN has been the topic of a number of recent research reports. Wall Street Zen raised shares of Precigen from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. JMP Securities upped their price target on shares of Precigen from $6.00 to $8.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 19th. HC Wainwright reiterated a "buy" rating and issued a $8.50 price objective on shares of Precigen in a research report on Tuesday, August 19th. JPMorgan Chase & Co. upgraded shares of Precigen from an "underweight" rating to a "neutral" rating in a report on Friday, August 15th. Finally, Citigroup restated an "outperform" rating on shares of Precigen in a report on Tuesday, August 19th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Precigen presently has an average rating of "Moderate Buy" and a consensus target price of $8.25.

Institutional Trading of Precigen

Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets acquired a new stake in Precigen in the fourth quarter valued at approximately $27,000. Apella Capital LLC purchased a new position in shares of Precigen during the 1st quarter valued at approximately $40,000. Voya Investment Management LLC lifted its stake in Precigen by 142.9% during the first quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 21,633 shares during the last quarter. ProShare Advisors LLC lifted its stake in Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock worth $58,000 after purchasing an additional 10,900 shares during the last quarter. Finally, Strs Ohio bought a new position in Precigen during the first quarter worth $70,000. Institutional investors and hedge funds own 33.51% of the company's stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.